GNMSF News and Press, Genmab A/S Dkk From 02/19/20

The following slide deck was published by Genmab A/S in conjunction with their 2019 Q4 earnings Read more ...

Genmab A/S (GNMSF) Q3 2019 Results Conference Call November 06, 2019 12:00 PM ET Company Participants Jan van de Winkel - President and CEO David Eatwell - CFO Conference Call Participants Kennen MacKay - RBC Capital Markets Wimal Kapadia - Bernstein Michael Schmidt - Gug...

Genmab A/S ( OTCPK:GNMSF ) announces that the European advisory group CHMP has adopted a positive opinion recommending approval of licensee Johnson & Johnson's (NYSE: JNJ ) Darzalex (daratumumab), combined with lenalidomide and dexamethasone, for treating newly diagnosed adult patients...

Genmab A/S (GNMSF) Q2 2019 Results Conference Call August 14, 2019 12:00 PM ET Company Participants Jan van de Winkel - President and CEO David Eatwell - CFO Conference Call Participants Kennen MacKay - RBC Capital Markets James Quigley - J.P. Morgan Wimal Kapadia - Berns...

The following slide deck was published by Genmab A/S in conjunction with their 2019 Q2 earnings Read more ...

Genmab ( OTCPK:GNMSF ) prices its IPO of 28.5M (from 27.8M) American Depositary Shares (ADSs) at $17.75 per ADS, each representing 1/10 of an ordinary share. More news on: Genmab A/S, Healthcare stocks news, IPO News, Read more ...

Genmab A/S ( OTCPK:GNMSF ) is up  2%  in Europe in reaction to Johnson & Johnson's Q2 results that included a 51% jump in Darzalex (daratumumab) sales to $774M. More news on: Genmab A/S, Genmab A/S, Healthcare stocks news, Stocks on the move, Read more ...

Genmab A/S ( OTCPK:GNMSF ) announces that licensee Janssen Biotech, a unit of Johnson & Johnson ( JNJ -5.2% ), has filed a marketing application with the FDA seeking approval for a subcutaneously administered formulation of multiple myeloma med Darzalex (daratumumab). More news on:...

Genmab A/S ( OTCPK:GNMSF -2.3% )  announces that a Phase 2 clinical trial, GRIFFIN , evaluating licensee Johnson & Johnson ( JNJ +0.3% ) unit Janssen Biotech's Darzalex (daratumumab), combined with Celgene's Revlimid (lenalidomide), Takeda's Velcade (bortezomib) and dexamethas...

The FDA approves Johnson & Johnson ( JNJ -0.5% ) unit Janssen Biotech's Darzalex (daratumumab), combined with Celgene's Revlimid (lenalidomide) and dexamethasone, for the first-line treatment of multiple myeloma (MM) patients who are ineligible for autologous stem cell transplantatio...